15 completed, 2 recruiting, 2 terminated, 1 unknown. 20 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Completed 15, Recruiting 2, Terminated 2, Unknown 1 |
| Phase 2 | 3 | Terminated 2, Completed 1 |
Follow Hypopituitarism: new trials by email Literature Review of Hypopituitarism trials Research Report on Hypopituitarism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Intranasal Oxytocin in Patients With Arginine-vasopressin Deficiency Intranasal Oxytocin (IN-OXT) 6 IU single dose, Intranasal Oxytocin (IN-OXT) 6 IU repeat dose, Placebo repeat dose - Vasopressin Deficiency | Phase 1 | Recruiting | Elizabeth Austen Lawson | 40 | 2025-09-10 | 2026-10-26 |
| A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD) GenSci134, Placebo, Recombinant Human Growth Hormone Injection (Norditropin®) - Safety, Tolerability | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 64 | 2025-06-09 | 2026-04-14 |
| A Study to Compare the Uptake Into the Blood of Two Strengths of Somapacitan After Injection Under the Skin in Healthy Subjects somapacitan - Healthy Volunteers, Growth Hormone Deficiency | Phase 1 | Completed | Novo Nordisk A/S | 33 | 2019-03-29 | 2019-08-06 |
| Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function. Somapacitan - Growth Hormone Disorder, Adult Growth Hormone Deficiency | Phase 1 | Completed | Novo Nordisk A/S | 34 | 2017-08-16 | 2019-05-24 |
| Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function Somapacitan - Growth Hormone Disorder, Adult Growth Hormone Deficiency | Phase 1 | Completed | Novo Nordisk A/S | 44 | 2017-06-20 | 2020-04-17 |
| Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers MOD-4023, Placebo - Growth Hormone Deficiency | Phase 1 | Completed | OPKO Health, Inc. | 42 | 2015-01-01 | 2019-09-30 |
| Evaluation of Pharmacokinetic and Pharmacodynamic Parameters of Somatropin Produced by Laboratory Blausiegel Indústria e Comércio Ltda., Compared to Saizen® From Laboratory Merck Serono S.A. Somatropin - GH Deficiency (GHD), Growth Retardation | Phase 1 | Unknown | Azidus Brasil | 32 | 2013-03-01 | 2012-09-25 |
| Phase 1 Safety Study of ALRN-5281 in Healthy Subjects ALRN-5281 0.015 mg/kg, ALRN-5281 0.05 mg/kg, ALRN-5281 0.15 mg/kg - Growth Hormone Deficiency | Phase 1 | Completed | Aileron Therapeutics, Inc. | 33 | 2013-01-01 | 2013-05-30 |
| A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency somapacitan, Norditropin NordiFlex® - Growth Hormone Disorder, Adult Growth Hormone Deficiency | Phase 1 | Completed | Novo Nordisk A/S | 35 | 2012-10-12 | 2020-12-24 |
| Versartis Trial in Children to Assess Long-Acting Growth Hormone Experimental: VRS-317 - Pediatric Growth Hormone Deficiency | Phase 1 / Phase 2 | Completed | Versartis Inc. | 64 | 2012-10-01 | 2022-07-26 |
| First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects somapacitan, placebo (somapacitan) - Growth Hormone Disorder, Adult Growth Hormone Deficiency | Phase 1 | Completed | Novo Nordisk A/S | 105 | 2012-01-16 | 2020-12-24 |
| Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers Somatropin, Placebo - Growth Hormone Deficiency | Phase 1 | Completed | HanAll BioPharma Co., Ltd. | 40 | 2011-09-01 | 2012-10-16 |
| Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children Niacin First, Placebo First, Dose-Establishing Study 1 Niacin 250mg - Obesity, Short Stature | Phase 1 / Phase 2 | Terminated | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 37 | 2011-07-01 | 2018-12-17 |
| VRS-317 in Adult Subjects With Growth Hormone Deficiency VRS-317 - Growth Hormone Deficiency | Phase 1 | Completed | Versartis Inc. | 50 | 2011-03-01 | 2012-07-23 |
| Crossover Study to Assess the Safety and Pharmacokinetic of Pegylated Somatropin(PEG Somatropin) in GHD Children somatropin AQ, pegylated somatropin - Growth Hormone Deficiency | Phase 1 | Completed | Changchun GeneScience Pharmaceutical Co., Ltd. | 12 | 2010-03-01 | 2012-06-14 |
| r-hGH Liquid Multidose Versus Freeze-dried Multidose Bioequivalence Trial r-hGH liquid (Saizen), r-hGH freeze-dried - Growth Failure, Growth Hormone Deficiency | Phase 1 | Completed | EMD Serono | 30 | 2008-07-01 | 2013-10-23 |
| Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors Recombinant Human Growth Hormone, Recombinant Human IGF-1 - Growth Hormone Deficiency | Phase 1 / Phase 2 | Terminated | Columbia University | 5 | 2008-01-01 | 2024-07-17 |
| A Multi-Dose Study to Assess Tolerability, Safety and Pharmacology of hGH-ViaDerm™ System in Adults With GH-Deficiency hGH-ViaDerm™ System (hGH or somatropin), hGH-ViaDerm™ System - Growth Hormone Deficiency | Phase 1 | Completed | Teva Neuroscience, Inc. | 60 | 2007-04-01 | 2013-09-02 |
| Safety Study of Syntropin (Human Growth Hormone) for the Treatment of Growth Hormone Deficiency Syntropin - Growth Hormone Deficiency | Phase 1 | Completed | Phage Pharmaceuticals, Inc. | 20 | 2004-08-01 | 2012-03-12 |
| A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin somatropin, placebo - Growth Hormone Disorder, Adult Growth Hormone Deficiency | Phase 1 | Completed | Novo Nordisk A/S | 86 | 2000-04-06 | 2017-02-27 |
Dwarfism, Pituitary (19) · Dwarfism (2) · Anxiety Disorders (1) · Bone Diseases (1) · Bone Diseases, Developmental (1) · Bone Diseases, Endocrine (1) · Brain Diseases (1) · Depression (1) · Diabetes Insipidus, Neurogenic (1) · Failure to Thrive (1) · Musculoskeletal Diseases (1) · Obesity (1) · Overweight (1) · Pituitary Diseases (1)
Central Nervous System Diseases (20) · Endocrine System Diseases (20) · Hypothalamic Diseases (20) · Nervous System Diseases (20) · Brain Diseases (19) · Pituitary Diseases (19) · Bone Diseases (18) · Bone Diseases, Developmental (18) · Bone Diseases, Endocrine (18) · Musculoskeletal Diseases (18) · Dwarfism (17) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Pathological Conditions, Signs and Symptoms (2)
Human Growth Hormone (7) · somapacitan (5) · Growth Hormone (3) · NNC0195-0092 (2) · Growth Hormone-Releasing Hormone (1) · Growth and Development (1) · Hormone Replacement Therapy (1) · Hormones (1) · Hormones, Hormone Substitutes, and Hormone Antagonists (1) · Insulin-Like Growth Factor Binding Protein 3 (1) · Insulin-Like Growth Factor I (1) · MOD-4023 (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (U.S.) (1) · Pharmacokinetics (1)
Novo Nordisk A/S (6) · Changchun GeneScience Pharmaceutical Co., Ltd. (2) · Versartis Inc. (2) · Aileron Therapeutics, Inc. (1) · Azidus Brasil (1) · Columbia University (1) · EMD Serono (1) · Elizabeth Austen Lawson (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · HanAll BioPharma Co., Ltd. (1) · OPKO Health, Inc. (1) · Phage Pharmaceuticals, Inc. (1) · Teva Neuroscience, Inc. (1)
United States (9) · Germany (4) · Brazil (1) · China (1) · Denmark (1) · Slovakia (1) · South Korea (1) · Sweden (1)
Bradley D Vince, D.O. (1) · Elizabeth A Lawson, MD, MMSc (1) · Hubert C Chen, M.D. (1) · Jack A Yanovski, M.D. (1) · Kyung-Sang Yu, Medicine (1) · Luo Xiaoping, Doctor (1) · Mark Kipnes, MD (1) · Michael Lissy, MD (1) · Noa Avisar, PhD (1) · Pamela U. Freda, M.D. (1)
PMID 29671202, PMID 33754315, PMID 20961422, PMID 23585663, PMID 25013997, PMID 26727076, PMID 33864240, PMID 38969919
2016 (2), 2018 (1)